Search | Page 12 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Anastasios Karadimitris, MD, PhD

    ... CD1d-restricted, GPI-specific T cells in paroxysmal nocturnal hemoglobinuria Original ... involving auto-reactive T cells targeting hematopoietic stem cells (HSC) leading to their profound depletion. It is widely ...

    Grant Recipient last updated 03/07/2017 - 9:50am.

  2. Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells

    ... and isogenic karyotypically normal induced pluripotent stem cells (iPSCs) from hematopoietic cells of MDS patients and show that the ...

    Research Article last updated 04/08/2015 - 9:33am.

  3. Pathogenesis of MDS: An Overview of molecular and non-molecular aspects of the disease

    ... a group of clonal disorders arising from hematopoietic stem cells generally characterized by inefficient hematopoiesis , ...

    Research Article last updated 05/12/2015 - 9:47am.

  4. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide

    ... Myelodysplastic syndrome (MDS) is a hematopoietic stem cell disorder primarily affecting CD34+ cells, characterized by ineffective hematopoiesis , often transforming ...

    Research Article last updated 04/17/2014 - 11:29am.

  5. Jill Whitney – Since my diagnosis, my mission has been to fight back

    ... regimen for transplant, and on May 25th, I received the stem cells of my 47-year old German donor. I encountered a few setbacks that ...

    Patient Chronicle last updated 05/26/2015 - 9:29am.

  6. Laboratory tests for paroxysmal nocturnal hemoglobinuria (PNH).

    ... Glycan class A (PIG-A) gene in the hematopoietic stem cells (HSC) of patients. The presence of these mutations leads to ...

    Research Article last updated 10/22/2013 - 3:44pm.

  7. Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going

    ... disorder characterized by the expansion of hematopoietic stem cells and progeny mature blood cells which are deficient in some surface ...

    Research Article last updated 05/22/2014 - 8:24am.

  8. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... therapy for patients with AML not eligible for stem cell transplant , and as maintenance therapy for patients with MDS or ... of azacitidine by increasing exposure to cycling malignant cells. In early phase trials, oral azacitidine (CC-486) in extended dosing ...

    Research Article last updated 12/09/2015 - 8:49am.

  9. Eltrombopag and improved hematopoiesis in refractory aplastic anemia

    ... cytopenia and a profound deficit in hematopoietic stem cells and progenitor cells. Thrombopoietin may increase the number of ...

    Research Article last updated 07/31/2012 - 2:24pm.

  10. Aplastic Anemia: Alternative Immunosuppressive Treatments and Eltrombopag. A report from the 2014 EBMT Educational Meeting from the Severe Aplastic Anaemia and Infectious Diseases Working Parties

    ... protection and/or stimulation of residual hematopoietic stem cells by eltrombopag seem an interesting strategy which, once combined ...

    Research Article last updated 03/02/2015 - 11:53am.